医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Oh Has Succeeded in the Research of LASEK on Reduction of Eye Damage

2016年07月21日 PM05:00
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

SEOUL, South Korea

Dr. Oh Jung Woo of EOS eye center released a surprising study that improves the safety of existing vision correction surgeries.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160721005430/en/

While the vision correction surgery has been operated for over three decades, the safety of refractive surgery is still doubtful.

Risks of LASIK include tearing of corneal flap and suction loss when the fixed part of the eyeball is loosened. LASEK has been an effective alternative for this problem, however, carrying out LASEK surgeries also demands at least 5 days for wound recovery, and is very painful due to damage on the epithelium after the surgery.

Dr. Oh’s six-year effort is especially highlighted in the factor analysis that minimizes the ablation amount. Proven by clinical outcomes, his new study also reduces the period of healing recovery up to two days as the range of damage of the corneal epithelium would be decreased only 40% the original method.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160721005430/en/

CONTACT

EOS eye center
Representative : Goeun Lim
TEL : +82-2-6097-0053
http://www.eoseye.co.kr/en/

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease